UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2
· Candidates in the LEO PDE4 inhibitor compound series have demonstrated potential to become ‘best-in-class’ based on Phase 2 studies in psoriasis (oral) and atopic dermatitis (topical) · PDE4 compound series strengthens UNION’s pipeline and offers potential synergies at organizational, financial and commercial levels Hellerup, Denmark, July 21, 2020 – UNION therapeutics A/S (“UNION”) today announced the completion of a transaction with LEO Pharma A/S (LEO Pharma) to acquire the global rights for the LEO PDE4 inhibitor compound series to be re-named UNI500. UNI500 is a series of